- Home
- GROW vs SER Comparison
GROW vs SER Comparison
Compare GROW & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | SER |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 29.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GROW | SER |
|---|---|---|
| Price | $3.25 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 129.8K | ★ 3.6M |
| Earning Date | 11-13-2025 | 03-23-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $8,546,000.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.02 | $1.65 |
| 52 Week High | $3.65 | $7.92 |
Technical Indicators
Market Signals| Indicator | GROW | SER |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 34.56 |
| Support Level | $2.88 | $1.65 |
| Resistance Level | $3.33 | $2.01 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 48.05 | 4.91 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.